Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP, Human Resources | December 12, 2014 | December 16, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date December 12, 2014 · Filed December 16, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,375 |
Ending reported balance
After 2014-12-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2014-12-12 · Sale · Disposed 300 · Balance 34,595 F1: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $119.73 (range $119.31 to $120.25). F3: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 2 · 2014-12-12 · Sale · Disposed 220 · Balance 34,375 F1: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F3: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $120.50 (range $120.45 to $120.57). |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 150 |
Reported balance
Holding disclosure · report date 2014-12-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 150 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $119.73 (range $119.31 to $120.25).
F3: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $120.50 (range $120.45 to $120.57).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2014 Filed Dec 16, 2014 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 220 | $120.50 | $26,510.00 |
DisclosureSEC source: 0001209191-14-075834 · doc4.xml · nonDerivative · entry 2 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,375 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $120.50 (range $120.45 to $120.57). Read SEC document |
| December 12, 2014 Filed Dec 16, 2014 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $119.73 | $35,919.00 |
DisclosureSEC source: 0001209191-14-075834 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,595 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $119.73 (range $119.31 to $120.25). F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 04, 2014 Filed Dec 5, 2014 21:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 937 | $0.00 Strike: $53.74 | $0.00 |
DisclosureSEC source: 0001209191-14-073398 · doc4.xml · derivative · entry 6 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,563 Underlying: Common Stock · 937 shares Expires 2022-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 09/04/2012. Read SEC document |
| December 04, 2014 Filed Dec 5, 2014 21:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $120.62 | $12,062.00 |
DisclosureSEC source: 0001209191-14-073398 · doc4.xml · nonDerivative · entry 4 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,895 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. Read SEC document |
| December 04, 2014 Filed Dec 5, 2014 21:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 337 | $119.36 | $40,224.32 |
DisclosureSEC source: 0001209191-14-073398 · doc4.xml · nonDerivative · entry 3 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,995 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $119.36 (range $118.95 to $119.82). Read SEC document |
| December 04, 2014 Filed Dec 5, 2014 21:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $118.40 | $59,200.00 |
DisclosureSEC source: 0001209191-14-073398 · doc4.xml · nonDerivative · entry 2 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,332 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $118.40 (range $117.92 to $118.86). F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 04, 2014 Filed Dec 5, 2014 21:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 937 | $53.74 | $50,354.38 |
DisclosureSEC source: 0001209191-14-073398 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2014 Filed Nov 19, 2014 21:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 153 | $111.87 | $17,116.11 |
DisclosureSEC source: 0001209191-14-069989 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,895 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $111.87 (range $111.85 to $111.88). F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 05, 2014 Filed Nov 7, 2014 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 937 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-14-067319 · doc4.xml · derivative · entry 6 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,438 Underlying: Common Stock · 937 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2013. Read SEC document |
| November 05, 2014 Filed Nov 7, 2014 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $114.31 | $11,431.00 |
DisclosureSEC source: 0001209191-14-067319 · doc4.xml · nonDerivative · entry 4 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,895 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 05, 2014 Filed Nov 7, 2014 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $113.13 | $22,626.00 |
DisclosureSEC source: 0001209191-14-067319 · doc4.xml · nonDerivative · entry 3 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,995 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $113.13 (range $112.89 to $113.37). Read SEC document |
| November 05, 2014 Filed Nov 7, 2014 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 637 | $112.07 | $71,388.59 |
DisclosureSEC source: 0001209191-14-067319 · doc4.xml · nonDerivative · entry 2 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,195 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $112.07 (range $111.69 to $112.46). F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 05, 2014 Filed Nov 7, 2014 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 937 | $45.11 | $42,268.07 |
DisclosureSEC source: 0001209191-14-067319 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2014 Filed Nov 3, 2014 22:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 20,000 | $0.01 | $200.00 |
DisclosureSEC source: 0001209191-14-065906 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,895 F1 · shares: Performance-based retention award that will vest if performance objectives are achieved prior to November 15, 2019. The award will vest on October 30, 2017 (or, if later, the day following the earnings release for the third quarter of 2017) if the Company achieves positive EBITDA for the 12-month period ending September 30, 2017. Between January 1, 2018 and November 15, 2019, if the Company achieves positive EBITDA for a 12-month period ending on a calendar quarter, the award will vest on the day following the applicable earnings release. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $111.52 | $11,152.00 |
DisclosureSEC source: 0001209191-14-061636 · doc4.xml · nonDerivative · entry 3 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,895 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $108.30 | $21,660.00 |
DisclosureSEC source: 0001209191-14-061636 · doc4.xml · nonDerivative · entry 2 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,995 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $108.30 (range $108.06 to $108.54). Read SEC document |
| October 01, 2014 Filed Oct 3, 2014 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 450 | $107.28 | $48,276.00 |
DisclosureSEC source: 0001209191-14-061636 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,195 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $107.28 (range $106.92 to $107.84). F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 7,844 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-060582 · doc4.xml · derivative · entry 13 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,906 Underlying: Common Stock · 7,844 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-14-060582 · doc4.xml · derivative · entry 12 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 1,500 shares Expires 2023-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/30/2013. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,875 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-14-060582 · doc4.xml · derivative · entry 11 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 1,875 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2013. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 2,813 | $0.00 Strike: $53.74 | $0.00 |
DisclosureSEC source: 0001209191-14-060582 · doc4.xml · derivative · entry 10 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,813 shares Expires 2022-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 09/04/2012. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,000 | $113.89 | $341,670.00 |
DisclosureSEC source: 0001209191-14-060582 · doc4.xml · nonDerivative · entry 8 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,645 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $113.89 (range $113.61 to $114.31). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,071 | $113.03 | $460,145.13 |
DisclosureSEC source: 0001209191-14-060582 · doc4.xml · nonDerivative · entry 7 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,645 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $113.03 (range $112.61 to $113.59). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,300 | $112.18 | $594,554.00 |
DisclosureSEC source: 0001209191-14-060582 · doc4.xml · nonDerivative · entry 6 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,716 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $112.18 (range $111.61 to $112.60). Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,800 | $111.29 | $200,322.00 |
DisclosureSEC source: 0001209191-14-060582 · doc4.xml · nonDerivative · entry 5 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,016 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $111.29 (range $110.61 to $111.58). F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,844 | $77.31 | $606,419.64 |
DisclosureSEC source: 0001209191-14-060582 · doc4.xml · nonDerivative · entry 4 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,500 | $83.36 | $125,040.00 |
DisclosureSEC source: 0001209191-14-060582 · doc4.xml · nonDerivative · entry 3 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,875 | $45.11 | $84,581.25 |
DisclosureSEC source: 0001209191-14-060582 · doc4.xml · nonDerivative · entry 2 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 1, 2014 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,813 | $53.74 | $151,170.62 |
DisclosureSEC source: 0001209191-14-060582 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2014 Filed Jul 17, 2014 22:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 27,500 | $0.00 Strike: $96.87 | $0.00 |
DisclosureSEC source: 0001209191-14-047895 · doc4.xml · derivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2024-07-14 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/15/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 938 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-14-008352 · doc4.xml · derivative · entry 7 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 938 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 62,750 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-008352 · doc4.xml · derivative · entry 6 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,750 Underlying: Common Stock · 62,750 shares Expires 2024-02-04 F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 738 | $77.83 | $57,438.54 |
DisclosureSEC source: 0001209191-14-008352 · doc4.xml · nonDerivative · entry 4 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,647 F2 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F4 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $77.83 (range $77.47 to $78.13). Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $76.82 | $15,364.00 |
DisclosureSEC source: 0001209191-14-008352 · doc4.xml · nonDerivative · entry 3 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,385 F2 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F3 · price: Open market sales reported on this line occurred at a weighted average price of $76.82 (range $76.49 to $77.14). F4 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 938 | $45.11 | $42,313.18 |
DisclosureSEC source: 0001209191-14-008352 · doc4.xml · nonDerivative · entry 2 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2014 Filed Feb 7, 2014 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 11,875 | $0.01 | $118.75 |
DisclosureSEC source: 0001209191-14-008352 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,647 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products. Read SEC document |
| December 12, 2013 Filed Dec 12, 2013 22:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 480 | $65.50 | $31,440.00 |
DisclosureSEC source: 0001209191-13-056695 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,772 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $65.50 (range $65.16 to $65.72). F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 04, 2013 Filed Dec 5, 2013 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 937 | $0.00 Strike: $53.74 | $0.00 |
DisclosureSEC source: 0001209191-13-055498 · doc4.xml · derivative · entry 4 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,313 Underlying: Common Stock · 937 shares Expires 2022-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 09/04/2012. Read SEC document |
| December 04, 2013 Filed Dec 5, 2013 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 937 | $67.38 | $63,135.06 |
DisclosureSEC source: 0001209191-13-055498 · doc4.xml · nonDerivative · entry 2 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,252 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $67.38 (range $67.00 to $67.72). F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 04, 2013 Filed Dec 5, 2013 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 937 | $53.74 | $50,354.38 |
DisclosureSEC source: 0001209191-13-055498 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2013 Filed Nov 19, 2013 21:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 150 | $61.05 | $9,157.50 |
DisclosureSEC source: 0001209191-13-053083 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,252 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 05, 2013 Filed Nov 7, 2013 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 937 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-051197 · doc4.xml · derivative · entry 5 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,188 Underlying: Common Stock · 937 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2013. Read SEC document |
| November 05, 2013 Filed Nov 7, 2013 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $66.11 | $6,611.00 |
DisclosureSEC source: 0001209191-13-051197 · doc4.xml · nonDerivative · entry 3 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,252 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 05, 2013 Filed Nov 7, 2013 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 837 | $65.00 | $54,405.00 |
DisclosureSEC source: 0001209191-13-051197 · doc4.xml · nonDerivative · entry 2 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,352 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 05, 2013 Filed Nov 7, 2013 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 937 | $45.11 | $42,268.07 |
DisclosureSEC source: 0001209191-13-051197 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2013 Filed Oct 31, 2013 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 938 | $0.00 Strike: $53.74 | $0.00 |
DisclosureSEC source: 0001209191-13-050003 · doc4.xml · derivative · entry 6 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 938 shares Expires 2022-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 09/04/2012. Read SEC document |
| October 29, 2013 Filed Oct 31, 2013 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 588 | $75.50 | $44,394.00 |
DisclosureSEC source: 0001209191-13-050003 · doc4.xml · nonDerivative · entry 4 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,252 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $75.50 (range $75.39 to $75.60). Read SEC document |
| October 29, 2013 Filed Oct 31, 2013 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,000 | $75.00 | $75,000.00 |
DisclosureSEC source: 0001209191-13-050003 · doc4.xml · nonDerivative · entry 3 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,840 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $75.00 (range $74.32 to $75.24). F3 · price: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 29, 2013 Filed Oct 31, 2013 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $72.68 | $7,268.00 |
DisclosureSEC source: 0001209191-13-050003 · doc4.xml · nonDerivative · entry 2 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,840 F1 · kind: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1. Read SEC document |
| October 29, 2013 Filed Oct 31, 2013 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 938 | $53.74 | $50,408.12 |
DisclosureSEC source: 0001209191-13-050003 · doc4.xml · nonDerivative · entry 1 Connolly Thomas · CIK 0001453943 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.